The muscle mass industry is undergoing a quiet but decisive recalibration. No longer merely a fitness aesthetic metric, muscle mass has emerged as a central biomarker for metabolic health, longevity, and surgical recovery. This week’s developments span three fronts: updated clinical guidelines for sarcopenia diagnosis, personalized protein recommendations based on individual anabolic thresholds, and the integration of AI-driven resistance training platforms into mainstream preventive care.

New Consensus on Sarcopenia: From “Low Muscle” to “Function-Adjusted Mass”

At the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) annual meeting in Brussels, a working group proposed a significant revision to the 2019 EWGSOP2 definition of sarcopenia. The draft recommendation, expected to be finalized by late 2025, suggests that muscle mass measurements should no longer be interpreted in isolation. Instead, the panel argues for a “function-adjusted mass” approach—combining appendicular lean mass (ALM) with grip strength and chair-stand timing into a composite score.

Lead author Dr. Helena Vandewalle, a geriatrician at KU Leuven, told attendees that the previous cutoff points (e.g., ALM/height² < 7.0 kg/m² for men) misclassified many older adults with obesity. “We are seeing a growing population of ‘sarcopenic obesity’ where raw mass appears normal but muscle quality is poor,” she explained. “The new framework uses a z-score relative to a healthy young reference population and adjusts for fat mass, so a 78-year-old woman with high BMI and low grip strength will not slip through the cracks.” This shift has immediate implications: pharmaceutical trials for selective androgen receptor modulators (SARMs) and myostatin inhibitors will need to adopt the composite end point, potentially extending trial timelines but improving clinical relevance.

Industry Response: Smart Scales and MRI-Based “Muscle Age” Enter Consumer Market

On the commercial side, two notable product launches this week signal a move beyond bioelectrical impedance analysis (BIA). Smart Scales unveiled its Body Pro 3 scale, which now incorporates a proprietary multi-frequency segmental algorithm that claims a 12% improvement in appendicular lean mass accuracy compared to its previous model, validated against DXA in a 340-subject study. More striking is the partnership between imaging startup Prenuvo and the longevity clinic network Fountain Life to offer a “Muscle Age Index” as part of routine full-body MRI screenings. The index calculates age-adjusted lean mass for the psoas, paraspinal, and quadriceps muscles, generating a percentile score that is now being used by primary care physicians to trigger early nutrition referrals.

“MRI-based muscle mass is the gold standard, but until now it was confined to research settings,” said Dr. Marcus Chen, chief medical officer at Fountain Life. “We are seeing a 300% year-over-year increase in patients requesting muscle health assessments, largely driven by GLP-1 receptor agonist users who want to track whether they are losing fat or precious lean tissue.” This concern is not unfounded. A meta-analysis published this month inJAMA Network Open, pooling 22 trials of semaglutide and tirzepatide, found that 38% of total weight lost was lean mass—a figure that varies widely by baseline protein intake and resistance training adherence.

Protein Timing and the “Anabolic Threshold” Debate

The nutrition science community is also converging on a more personalized approach to protein distribution. A new position paper from the International Society of Sports Nutrition (ISSN) moves away from the generic “1.6 g/kg/day” recommendation for active adults. Instead, the authors propose a model based on the “per-meal anabolic threshold”—the minimum leucine content (approximately 2.5–3.0 g) required to maximally stimulate muscle protein synthesis (MPS) in older adults. The paper cites recent work from Maastricht University showing that older men with low habitual protein intake require 30% more leucine per meal to achieve the same MPS response as younger counterparts, due to anabolic resistance.

The practical translation: a 70 kg older adult may need four meals with 35–40 g protein each, rather than three larger meals, to sustain muscle mass. This has direct implications for the food industry. Several major dairy and plant-based protein manufacturers, including Arla Foods Ingredients and Roquette, have announced that they are reformulating ready-to-drink shakes to include a standardized “senior leucine dose” of 3.2 g per bottle, with a target launch in Q3 202 5. Meanwhile, the supplement brand Thorne introduced a new “MyoGuard” formula containing 5 g of leucine plus 1.5 g of HMB (beta-hydroxy-beta-methylbutyrate), citing a recent 12-week RCT in which the combination preserved quadriceps cross-sectional area in adults over 65 during a 40% caloric deficit.

Digital Resistance Training: Evidence Base Expands for Remote Delivery

The telehealth muscle mass space saw a pivotal development with the publication of the “MuscleTech Remote Trial” inThe Lancet Healthy Longevity. In a 16-week, 412-participant study, adults aged 60–85 with low baseline ALM were randomized to either a center-based supervised program or a home-based program using the Oxefit XS1 smart resistance machine, which automatically adjusts load based on velocity-based training algorithms. Results showed no significant difference in lean mass gains (1.1 kg vs. 1.0 kg) or in functional outcomes (sit-to-stand power, stair climb time). Adherence was actually higher in the remote group (87% vs. 74%), driven by flexible scheduling and gamified feedback loops.

This trial is expected to accelerate reimbursement decisions. In the United States, the Centers for Medicare & Medicaid Services (CMS) has not yet approved a specific CPT code for digital therapeutic resistance training, but the National Institute on Aging has funded a follow-up cost-effectiveness analysis. Dr. Priya Raghavan, a physical medicine specialist at Johns Hopkins who was not involved in the trial, noted that “the barrier is no longer technology, but regulatory infrastructure. We need a clear billing pathway for ‘muscle preservation therapy’ analogous to cardiac rehab.” A working group of the American Geriatrics Society is drafting a proposal to submit to CMS by June 2025.

Expert Outlook: Muscle Mass as the Fifth Vital Sign

Across these developments, a unifying theme emerges: muscle mass is being repositioned from a niche performance metric to a core vital sign for aging populations. Dr. Vandewalle summarized the sentiment: “We measure blood pressure, glucose, and cholesterol. But we rarely measure the one tissue that regulates glucose disposal, immune function, and fall risk. That is changing. The next five years will see muscle mass integrated into every electronic health record, not as an optional field, but as a required parameter.”

The immediate commercial winners are likely to be companies that combine accurate measurement (DXA, MRI, or validated BIA) with actionable, personalized interventions—whether dietary leucine optimization, digital strength coaching, or pharmacologic adjuncts. The losers may be those who continue to market muscle mass as a vanity metric, as regulators and payers increasingly demand functional end points. For clinicians, the takeaway is clear: start asking about muscle mass today, not because it is trendy, but because the evidence base has finally caught up with the biology.